EQT to Acquire Qiagen in €10.8 Billion All-Cash Takeover
Qiagen (QGEN) has entered into a definitive agreement to be acquired by the Swedish private equity firm EQT through its holding company, Crown NL Bidco. The all-cash offer is valued at €46.50 per share, bringing the total enterprise value of the European molecular testing specialist to approximately €10.8 billion. The deal represents a significant consolidation in the life sciences and diagnostics sector. By taking the company private, EQT aims to leverage Qiagen's position in molecular testing within a private equity framework, potentially accelerating long-term strategic shifts away from public market scrutiny.
Topics: Acquisition Molecular Testing Private Equity
Read the full article at Seeking Alpha
Part of the story Qiagen Shares Rise on Reports of Potential €9.6 Billion Acquisition by EQT AB (2 articles)